BMJ  2008;336:854 (19 April), doi:10.1136/bmj.39552.490856.4E

News

New combined pill to treat malaria is launched

John Zarocostas

1 Geneva

The first 150 words of the full text of this article appear below.

A new low cost, first line, fixed dose combination drug to treat uncomplicated falciparum malaria in Latin America and South East Asia is expected to lower the number of cases of the disease and reduce the number of hospitalisations.

The combination of artesunate and mefloquine in a single tablet has been produced as a "non-exclusive, not for profit public good," said the Drugs for Neglected Diseases Initiative, which coordinated the project.

"The drug combination in the same tablet will improve the management of cases," said Bernard Pecoul, executive director of the initiative, which is the joint project of seven organisations, including the charity Médecins Sans Frontières and France’s Pasteur Institute.

The new product, which avoids the need for a two tablet regimen, "will make it more possible to use [treatment] more simply in the field," said Jean-René Kiechel, the initiative’s senior project manager for malaria. The fixed dose would also . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Student BMJ

Risk of surgery for inflammatory bowel disease: record linkage studies

What can you learn from this BMJ paper? Read Leanne Tite's Paper+

www.student.bmj.com

Listen to the latest BMJ Interview